These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 28251556)

  • 1. Retrospective Study on the Impact of Adherence in Achieving Glycemic Goals in Type 2 Diabetes Mellitus Patients Receiving Canagliflozin.
    Buysman EK; Anderson A; Bacchus S; Ingham M
    Adv Ther; 2017 Apr; 34(4):937-953. PubMed ID: 28251556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world Canagliflozin Utilization: Glycemic Control Among Patients With Type 2 Diabetes Mellitus-A Multi-Database Synthesis.
    Chow W; Miyasato G; Kokkotos FK; Bailey RA; Buysman EK; Henk HJ
    Clin Ther; 2016 Sep; 38(9):2071-82. PubMed ID: 27596020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness, treatment durability, and treatment costs of canagliflozin and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes in the USA.
    Singhal M; Tan H; Coleman CI; Han M; Nguyen C; Ingham M
    BMJ Open Diabetes Res Care; 2019; 7(1):e000704. PubMed ID: 31798890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world evaluation of glycemic control among patients with type 2 diabetes mellitus treated with canagliflozin versus dipeptidyl peptidase-4 inhibitors.
    Thayer S; Chow W; Korrer S; Aguilar R
    Curr Med Res Opin; 2016 Jun; 32(6):1087-96. PubMed ID: 26938635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
    Grabner M; Peng X; Geremakis C; Bae J
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysis.
    Buysman EK; Chow W; Henk HJ; Rupnow MF
    BMC Endocr Disord; 2015 Nov; 15():67. PubMed ID: 26527413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An observational study of glycemic control in canagliflozin treated patients.
    Meckley LM; Miyasato G; Kokkotos F; Bumbaugh J; Bailey RA
    Curr Med Res Opin; 2015 Aug; 31(8):1479-86. PubMed ID: 25986535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics and short-term outcomes of patients with type 2 diabetes mellitus treated with canagliflozin in a real-world setting.
    Buysman EK; Chow W; Henk HJ; Rupnow MF
    Curr Med Res Opin; 2015 Jan; 31(1):137-43. PubMed ID: 25356602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycemic Control Outcomes After Canagliflozin Initiation: Observations in a Medicare and Commercial Managed Care Population in Clinical Practice.
    Bailey RA; Schwab P; Xu Y; Pasquale M; Renda A
    Clin Ther; 2016 Sep; 38(9):2046-2057.e2. PubMed ID: 27567160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of medication adherence and persistence on clinical and economic outcomes in patients with type 2 diabetes treated with liraglutide: a retrospective cohort study.
    Buysman EK; Liu F; Hammer M; Langer J
    Adv Ther; 2015 Apr; 32(4):341-55. PubMed ID: 25832470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.
    Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P
    Endocr Pract; 2018 Mar; 24(3):273-287. PubMed ID: 29547044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HbA
    Thayer S; Aguilar R; Korrer S; Chow W
    Clin Ther; 2017 Oct; 39(10):2061-2072. PubMed ID: 28943114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Canagliflozin provides greater attainment of both HbA1c and body weight reduction versus sitagliptin in patients with type 2 diabetes.
    Schernthaner G; Lavalle-González FJ; Davidson JA; Jodon H; Vijapurkar U; Qiu R; Canovatchel W
    Postgrad Med; 2016 Nov; 128(8):725-730. PubMed ID: 27391951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A real-world analysis of glycemic control among patients with type 2 diabetes treated with canagliflozin versus dapagliflozin.
    Blonde L; Patel C; Bookhart B; Pfeifer M; Chen YW; Wu B
    Curr Med Res Opin; 2018 Jun; 34(6):1143-1152. PubMed ID: 29595326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world glycemic, blood pressure, and weight control in patients with type 2 diabetes mellitus treated with canagliflozin-an electronic health-record-based study.
    Lefebvre P; Pilon D; Robitaille MN; Lafeuille MH; Chow W; Pfeifer M; Duh MS
    Curr Med Res Opin; 2016 Jun; 32(6):1151-9. PubMed ID: 27115475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Retrospective Database Study Comparing Diabetes-Related Medication Adherence and Health Outcomes for Mail-Order Versus Community Pharmacy.
    Schwab P; Racsa P; Rascati K; Mourer M; Meah Y; Worley K
    J Manag Care Spec Pharm; 2019 Mar; 25(3):332-340. PubMed ID: 30816817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of adherence and weight loss on glycemic control in patients with type 2 diabetes: cohort analyses of integrated medical record, pharmacy claims, and patient-reported data.
    McAdam-Marx C; Bellows BK; Unni S; Wygant G; Mukherjee J; Ye X; Brixner DI
    J Manag Care Spec Pharm; 2014 Jul; 20(7):691-700. PubMed ID: 24967522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canagliflozin treatment of Hispanic and non-Hispanic patients with type 2 diabetes in a US managed care setting.
    Chow W; Buysman E; Rupnow MF; Aguilar R; Henk HJ
    Curr Med Res Opin; 2016; 32(1):13-22. PubMed ID: 26414434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world Clinical Outcomes Among Patients With Type 2 Diabetes Receiving Canagliflozin at a Specialty Diabetes Clinic: Subgroup Analysis by Baseline HbA
    Johnson JF; Parsa R; Bailey RA
    Clin Ther; 2017 Jun; 39(6):1123-1131. PubMed ID: 28495028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individualized HbA
    Lautsch D; Boggs R; Wang T; Gonzalez C; Milligan G; Rajpathak S; Malkani S; McLeod E; Carroll J; Higgins V
    Adv Ther; 2022 Feb; 39(2):1016-1032. PubMed ID: 34951678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.